Loss of prostaglandin Dâ‚‚synthase : a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma

Cathy A. Payne; Sanaz Maleki; Marinella Messina; Maree G. O'Sullivan; Glenn Stone; Nathan R. Hall; Jonathon F. Parkinson; Helen R. Wheeler; Raymond J. Cook; Michael T. Biggs; Nicholas S. Little; Charles Teo; Bruce G. Robinson; Kerrie L. McDonald

doi:10.1158/1535-7163.MCT-08-0629

Loss of prostaglandin Dâ‚‚synthase : a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma

Cathy A. Payne, Sanaz Maleki, Marinella Messina, Maree G. O'Sullivan, Glenn Stone, Nathan R. Hall, Jonathon F. Parkinson, Helen R. Wheeler, Raymond J. Cook, Michael T. Biggs, Nicholas S. Little, Charles Teo, Bruce G. Robinson, Kerrie L. McDonald

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

Reduction in the mRNA and protein expression of lipocalin-like prostaglandin Dâ‚‚(PGDâ‚‚) synthase (PGDS), the main arachidonic acid metabolite produced in neurons and glial cells of the central nervous system, is a significant biological event involved in the malignant progression of astrocytomas and is predictive of poor survival. In vitro, the addition of the main PGDS metabolite, PGDâ‚‚, to A172 glioblastoma cells devoid of PGDS resulted in antiproliferative activity and cell death. In vitro PGDâ‚‚substitution also enhanced the efficacy of cyclo-oxygenase-2i nhibitors. This finding has exciting implications for early interventional efforts for the grade 2 and 3 astrocytomas.

Original language	English
Pages (from-to)	3420-3428
Number of pages	9
Journal	Molecular Cancer Therapeutics
Volume	7
Issue number	10
DOIs	https://doi.org/10.1158/1535-7163.MCT-08-0629
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1535-7163.MCT-08-0629

Cite this

Payne, C. A., Maleki, S., Messina, M., O'Sullivan, M. G., Stone, G., Hall, N. R., Parkinson, J. F., Wheeler, H. R., Cook, R. J., Biggs, M. T., Little, N. S., Teo, C., Robinson, B. G., & McDonald, K. L. (2008). Loss of prostaglandin Dâ‚‚synthase : a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma. Molecular Cancer Therapeutics, 7(10), 3420-3428. https://doi.org/10.1158/1535-7163.MCT-08-0629

@article{b285f81873fb4936b8ffe13b6018f07c,

title = "Loss of prostaglandin D{\^a}‚‚synthase : a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma",

abstract = "Reduction in the mRNA and protein expression of lipocalin-like prostaglandin D{\^a}‚‚(PGD{\^a}‚‚) synthase (PGDS), the main arachidonic acid metabolite produced in neurons and glial cells of the central nervous system, is a significant biological event involved in the malignant progression of astrocytomas and is predictive of poor survival. In vitro, the addition of the main PGDS metabolite, PGD{\^a}‚‚, to A172 glioblastoma cells devoid of PGDS resulted in antiproliferative activity and cell death. In vitro PGD{\^a}‚‚substitution also enhanced the efficacy of cyclo-oxygenase-2i nhibitors. This finding has exciting implications for early interventional efforts for the grade 2 and 3 astrocytomas.",

author = "Payne, {Cathy A.} and Sanaz Maleki and Marinella Messina and O'Sullivan, {Maree G.} and Glenn Stone and Hall, {Nathan R.} and Parkinson, {Jonathon F.} and Wheeler, {Helen R.} and Cook, {Raymond J.} and Biggs, {Michael T.} and Little, {Nicholas S.} and Charles Teo and Robinson, {Bruce G.} and McDonald, {Kerrie L.}",

year = "2008",

doi = "10.1158/1535-7163.MCT-08-0629",

language = "English",

volume = "7",

pages = "3420--3428",

journal = "Molecular Cancer Therapeutics",

issn = "1535-7163",

publisher = "American Association for Cancer Research",

number = "10",

}

Payne, CA, Maleki, S, Messina, M, O'Sullivan, MG, Stone, G, Hall, NR, Parkinson, JF, Wheeler, HR, Cook, RJ, Biggs, MT, Little, NS, Teo, C, Robinson, BG & McDonald, KL 2008, 'Loss of prostaglandin Dâ‚‚synthase : a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma', Molecular Cancer Therapeutics, vol. 7, no. 10, pp. 3420-3428. https://doi.org/10.1158/1535-7163.MCT-08-0629

TY - JOUR

T1 - Loss of prostaglandin Dâ‚‚synthase : a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma

AU - Payne, Cathy A.

AU - Maleki, Sanaz

AU - Messina, Marinella

AU - O'Sullivan, Maree G.

AU - Stone, Glenn

AU - Hall, Nathan R.

AU - Parkinson, Jonathon F.

AU - Wheeler, Helen R.

AU - Cook, Raymond J.

AU - Biggs, Michael T.

AU - Little, Nicholas S.

AU - Teo, Charles

AU - Robinson, Bruce G.

AU - McDonald, Kerrie L.

PY - 2008

Y1 - 2008

N2 - Reduction in the mRNA and protein expression of lipocalin-like prostaglandin Dâ‚‚(PGDâ‚‚) synthase (PGDS), the main arachidonic acid metabolite produced in neurons and glial cells of the central nervous system, is a significant biological event involved in the malignant progression of astrocytomas and is predictive of poor survival. In vitro, the addition of the main PGDS metabolite, PGDâ‚‚, to A172 glioblastoma cells devoid of PGDS resulted in antiproliferative activity and cell death. In vitro PGDâ‚‚substitution also enhanced the efficacy of cyclo-oxygenase-2i nhibitors. This finding has exciting implications for early interventional efforts for the grade 2 and 3 astrocytomas.

AB - Reduction in the mRNA and protein expression of lipocalin-like prostaglandin Dâ‚‚(PGDâ‚‚) synthase (PGDS), the main arachidonic acid metabolite produced in neurons and glial cells of the central nervous system, is a significant biological event involved in the malignant progression of astrocytomas and is predictive of poor survival. In vitro, the addition of the main PGDS metabolite, PGDâ‚‚, to A172 glioblastoma cells devoid of PGDS resulted in antiproliferative activity and cell death. In vitro PGDâ‚‚substitution also enhanced the efficacy of cyclo-oxygenase-2i nhibitors. This finding has exciting implications for early interventional efforts for the grade 2 and 3 astrocytomas.

UR - http://handle.uws.edu.au:8081/1959.7/555628

U2 - 10.1158/1535-7163.MCT-08-0629

DO - 10.1158/1535-7163.MCT-08-0629

M3 - Article

SN - 1535-7163

VL - 7

SP - 3420

EP - 3428

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

IS - 10

ER -

Loss of prostaglandin Dâ‚‚synthase : a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this